Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP98535.RABamqQaru8UrDUcf66S07W32SIWa_YvqTOojhOPaxHSA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP98535.RABamqQaru8UrDUcf66S07W32SIWa_YvqTOojhOPaxHSA130_assertion type Assertion NP98535.RABamqQaru8UrDUcf66S07W32SIWa_YvqTOojhOPaxHSA130_head.
- NP98535.RABamqQaru8UrDUcf66S07W32SIWa_YvqTOojhOPaxHSA130_assertion description "[The 6-month overall survival rate of 36% observed on this study failed to meet the primary survival objective. Thus, cetuximab alone cannot be recommended in the second-line treatment of metastatic esophageal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP98535.RABamqQaru8UrDUcf66S07W32SIWa_YvqTOojhOPaxHSA130_provenance.
- NP98535.RABamqQaru8UrDUcf66S07W32SIWa_YvqTOojhOPaxHSA130_assertion evidence source_evidence_literature NP98535.RABamqQaru8UrDUcf66S07W32SIWa_YvqTOojhOPaxHSA130_provenance.
- NP98535.RABamqQaru8UrDUcf66S07W32SIWa_YvqTOojhOPaxHSA130_assertion SIO_000772 20631636 NP98535.RABamqQaru8UrDUcf66S07W32SIWa_YvqTOojhOPaxHSA130_provenance.
- NP98535.RABamqQaru8UrDUcf66S07W32SIWa_YvqTOojhOPaxHSA130_assertion wasDerivedFrom gad-20150221 NP98535.RABamqQaru8UrDUcf66S07W32SIWa_YvqTOojhOPaxHSA130_provenance.
- NP98535.RABamqQaru8UrDUcf66S07W32SIWa_YvqTOojhOPaxHSA130_assertion wasGeneratedBy ECO_0000203 NP98535.RABamqQaru8UrDUcf66S07W32SIWa_YvqTOojhOPaxHSA130_provenance.